Astellas Buys Perseid Joint Venture With Maxygen For $76 Million
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma said it has completed its buyout of Perseid Therapeutics for $76 million, making the firm a wholly owned subsidiary